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Accurate unbound solution 3D-structures of ligands provide unique opportunities for medicinal chemis-
try and, in particular, a context to understand binding thermodynamics and kinetics. Previous methods of
deriving these 3D-structures have had neither the accuracy nor resolution needed for drug design and
have not yet realized their potential. Here, we describe and apply a NMR methodology to the aminogly-
coside streptomycin that can accurately quantify accessible 3D-space and rank the occupancy of
observed conformers to a resolution that enables medicinal chemistry understanding and design. Impor-
tantly, it is based upon conventional small molecule NMR techniques and can be performed in physiolog-
ically-relevant solvents. The methodology uses multiple datasets, an order of magnitude more
experimental data than previous NMR approaches and a dynamic model during reﬁnement, is indepen-
dent of computational chemistry and avoids the problem of virtual conformations. The reﬁned set of solu-
tion 3D-shapes for streptomycin can be grouped into two major families, of which the most populated is
almost identical to the 30S ribosomal subunit bioactive shape. We therefore propose that accurate
unbound ligand solution conformations may, in some cases, provide a subsidiary route to bioactive shape
without crystallography. This experimental technique opens up new opportunities for drug design and
more so when complemented with protein co-crystal structures, SAR data and pharmacophore modeling.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Small molecules with high afﬁnity for their targets bind using a
particular 3D-shape and interaction network. This 3D-interaction
map, or pharmacophore, can be used as a blueprint to enable the
efﬁcient optimization and design of molecules during the drug dis-
covery process. Molecules designed to prefer the 3D-structure
adopted in the bound state trend to higher association constants
due to their conformational pre-organization.1 Documented suc-
cesses of such conformational design strategies include the inhibi-
tion of HIV protease2 and BACE1.3 Similarly, many natural products
and endogenous ligands take advantage of this conformational
pre-organisation phenomenon by presenting a restricted group of
conformations to a binding partner, retinol being a good example.4Indeed, a signiﬁcant number of natural products are based on rigid
templates and frameworks that have limited conformational vari-
ability, e.g., alkaloids and steroids.5 In energetic terms, this confor-
mational pre-organization lowers the conformational entropy
penalty for transition from the ligand’s unbound set of conforma-
tions to its bioactive conformation(s).6 Therefore, as an important
component of the observed binding afﬁnity, a molecular under-
standing of the conformational changes upon receptor binding that
a ligand undergoes could be harnessed to rationalize structure-
activity relationships and design ligands with better afﬁnity.7
Furthermore, when a ligand’s bioactive conformation cannot be di-
rectly measured (e.g., due to difﬁculties in crystallizing the target),
the unbound conformation(s) of a high-afﬁnity ligand can provide
an alternative route to its bioactive conformation precisely because
it is likely to be pre-organized towards the bioactive conformation
to some extent, and this principle can enable ligand-based ap-
proaches to drug discovery and optimization.8
SolutionNMR is themethodof choice formeasuring theunbound
shapes of ligands because conformational restraints for use in
3D-molecular reﬁnement can be directly measured from the ligand
in its near-natural state. Conformational restraints typically
used are spin relaxation data (e.g., NOESY, ROESY), scalar couplings9
and residual dipolar couplings.10 The most widely-employed
Figure 1. Chemical structure of streptomycin in aqueous solution. Streptomycin
comprises streptidine (S1), streptose (R2, a ribose derivative) and glucosamine (G3)
residues. Heavy atom designations within each residue are shown; prochiral atoms
are indicated (pro-S, pro-R, pro-E, pro-Z). Glycosidic linkage and exocyclic torsion
angles are marked and were deﬁned as follows: /1,2 = R2 O4–R2 C1–S1 O4–S1 C4;
w1,2 = R2 C1–S1 O4–S1 C4–S1 C3; /2,3 = G3 O5–G3 C1–R2 O2–R2 C2; w2,3 = G3 C1–
R2 O2–R2 C2–R2 C1; v1(S1) = C6–C1–N1–C10; v3(S1) = C2–C3–N3–C3’; v3(R2) = C2–
C3–C3’–O31; v2(G3) = C1–C2–N2–C2’; v5(G3) = C4–C5–C6–O6.
C. D. Blundell et al. / Bioorg. Med. Chem. 21 (2013) 4976–4987 49773D-reﬁnement approach11–13 attempts to ﬁt the restraints to a sin-
gle rigid conformation, but the presence of multiple rapidly inter-
changing conformations often leads this process to produce virtual
conformations that do not correspond to actual conformations ever
adopted by the molecule.14 Other approaches try to address this
problem by introducing ligand conformational ﬂexibility with com-
putational modeling methods.15–19 These have had mixed success
because themethods variously rely upon accuratelymodeling com-
plex electronic molecular orbital hybridization and strong interac-
tions with solvent, neither of which are straightforward. For
example, the method NAMFIS could not be applied to a polar mole-
cule because current force ﬁelds did not uniformly represent its con-
formational proﬁle.20 Yet other approaches attempt to reconstruct
an analytical probability distribution for rotation about torsional
angles fromNMRdata.21 These have provenunpopular because they
are very complicated and have only been reduced to practice for an
individual bond and are therefore of little practical value for confor-
mational design.
Here, we present and demonstrate a new NMR methodology
that is able to accurately quantify the conformations of unbound
ligands in solution (i.e., to effectively reproduce the Boltzmann dis-
tribution) to the resolution needed for drug design. The technique
uses multiple datasets and a dynamic model during reﬁnement of
the ligand, does not employ computational chemistry techniques
to mimic molecular ﬂexibility and avoids the problem of virtual
conformations. We applied the method to the aminoglycoside
streptomycin (Fig. 1) and found that the resultant dynamic 3D-
structure was best described by two families of conformations
(Fig. 2). The dominant conformational family has an identical 3D-
structure to the observed bioactive conformation of streptomycin
when bound to the 30S ribosomal subunit, consistent with the
expectation that streptomycin is conformationally pre-organized
for binding to its target.
Accurate unbound ligand 3D-structures as determined here can
be used to provide detail on the contribution of ligand conforma-
tional reorganization energies on binding and can, moreover, be
used in lieu of co-crystal data as predictors of the bioactive confor-
mation, particularly in the case of high afﬁnity ligands. These prox-
ies for the bioactive conformation could be used throughout hit
identiﬁcation and lead optimization processes both to discover
new chemistry starting points and to drive the optimization of
afﬁnity and selectivity of compounds using conformational design.
2. Materials and methods
2.1. NMR sample preparation
Streptomycin was purchased from Sigma–Aldrich (sulfate salt,
product number S1937, CAS number [3810-74-0]). Samples for
data acquisition were prepared at a range of concentrations (0.1–
50 mM) in solutions of 100% D2O or 90%:10% (v/v) H2O/D2O, pH⁄
6.0, and contained 1 mM d6-DSS as an internal reference.
2.2. Chemical shift assignment
All 1H, 15N and 13C chemical shifts and pertinent coupling con-
stants of streptomycin in aqueous solution at pH 6.0 were assigned
using standard 1D and 2D-NMR experiments at 600 MHz (refer to
Fig. 1 for nomenclature and Supplementary Tables S1–S8 for
assignment data). Chemical shifts and coupling constants indicate
that the aldehyde group of streptomycin at R2 C30 was predomi-
nantly hydrated (96 ± 1%; 5 C in H2O) in aqueous solution, giving
the gem-diol form as shown in Figure 1. Coupling constants, chem-
ical shifts and the absence of any speciﬁc inter-residue correlations
in 13C- and 15N-HMBC spectra preclude the proposed aldehyde-cy-
clized forms of streptomycin in aqueous solution.22–24Chemical shifts and conformation-dependent 3JHH coupling con-
stants were measured at several solute concentrations (0.1–50 mM
streptomycin) and at different temperatures (5 –35 C). Since the
differences in 1H chemical shifts between these conditions are
small (<0.1 ppm), all temperature-induced perturbations occur lin-
early (see Supplementary Figure S1 for regression plots), and no
3JHH coupling constant changes by more than 0.2 Hz, it was con-
cluded that streptomycin does not signiﬁcantly self-associate in
aqueous solution and its dynamic 3D-structure is insensitive to
changes in temperature in the physiological range. The glucosa-
mine secondary amine (G3 N2) was fully protonated at pH 6.0 (dis-
tinct HN21 and HN22 protons were observed in COSY
experiments) and therefore (including the two guanidinium
groups) streptomycin carries a +3 charge under physiological con-
ditions. Pro-chiral stereo-assignments were determined during
structure calculations (see below).
2.3. Structural restraint measurement
2.3.1. Conformation-dependent scalar couplings
Three-bond homonuclear coupling constants (3JHH) used for
structure determination were measured from 1H-1D spectra re-
corded at 900 MHz (16384 complex points, dwell-time 92.5 ls)
on both D2O and H2O samples. Scalar couplings were measured
by a resonance line-ﬁtting algorithm that moved a set of modeled
scalar couplings until a ﬁt was obtained with the experimental
multiplet pattern;25 the Lorentzian line width used by the
Figure 2. The dynamic 3D-structure of streptomycin in aqueous solution is remarkably well-deﬁned in spite of the presence of multiple rotatable bonds (see Fig. 1). Each
rotatable bond in streptomycin librates around one or more preferred macrostates (refer to Table 2), which can be represented by a uniformly weighted ensemble of 3D-
structures whose distribution collectively accounts for the observed experimental data (A; the set of conformational microstates). This ensemble representation can be
meaningfully reduced to a view where each rotatable bond is shown at the average position of each and every macrostate adopted (B). The bimodal behavior of the F2–G3
glycosidic linkage (/2,3 andw2,3) gives rise to two principal conformational families (C, D; left vs right, Family 1 vs Family 2), between which the overall shape of streptomycin
is signiﬁcantly different. These two families are shown in the set of macrostates (C) and transparent overlay views (D). The overlay captures the relationship between the
extent of libration (grey; microstates) about each macrostate (black) for each family. The position of each residue is labeled; all molecules have been overlaid on the heavy
atoms of the R2 furanose ring. Carbon atoms are shown in white, nitrogen in blue and oxygen in red; hydrogen atoms have been omitted for clarity.
4978 C. D. Blundell et al. / Bioorg. Med. Chem. 21 (2013) 4976–4987algorithm was also obtained as part of the ﬁt. The resultant tabu-
lated data are presented in Supplementary Table S7. For each cou-
pling constant a suitable Karplus relation (typically an incarnation
of the Altona–Hasnoot equation26) for the torsion in question was
associated with the raw measurement to produce a structural re-straint. Even though the couplings were measured with an error
of 0.1–0.4 Hz, because the Karplus equations only have a predictive
accuracy of 1 Hz,26 this value was used as the error for the re-
straint. The derived structural restraints are presented in Supple-
mentary Table S9.
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A 2D-NOESY spectrum with pre-saturation for water suppres-
sion was acquired on a 50 mM 100% D2O sample at 900 MHz and
5 C with a mixing time of 700 ms (acquisition dimension—2048
complex points, dwell-time 92.5 ls; indirect dimension—256 com-
plex points, dwell-time 109.9 ls). A second 2D-NOESY spectrum
with WATERGATE water suppression27 was recorded using a
50 mM 90%:10% (v/v) H2O/D2O sample at 600 MHz and 5 C with
a mixing time of 600 ms (acquisition dimension—4096 complex
points, dwell-time 138.9 ls; indirect dimension—128 complex
points, dwell-time 138.9 ls). Detailed experimental information
was extracted from these 2D-NOESY experiments by measuring
the absolute values of cross-peak heights directly from the NMR
spectra. All possible cross-peak positions were measured, including
overlapping peaks and those that were found to be unambiguously
zero, but excluding positions that could not be measured due to
NMR artifacts. Although the majority of hydroxyl protons in strep-
tomycin were observed and assigned at 5 C, they remained in such
fast exchange that it was not possible to measure structural re-
straints to them and they are therefore excluded from the 3D-
structure described here. Due to the resolution of the spectrum
in the acquisition dimension, the ﬁne structure for each cross-peak
was visible. Each component of the ﬁne structure was base-lined
and rescaled by multiplication by suitable scaling factors to allow
the correct equivalent peak-height value for one mole abundance
of protons to be calculated. These scaling factors were readily cal-
culated for every ﬁne structure component from the coupling con-
stants already measured for each proton. For example, each
component in a doublet had a scaling factor of 2, whereas those
in a triplet were 4, 2 and 4. The mean peak-height value calculated
from the ﬁne structure components for each cross-peak was taken
as the peak-height value for that cross-peak. In this way, the true
relative peak-height for each cross-peak in the 2D-NOESY spec-
trum was measured while compensating for the problem of the
different line-shapes of each proton making peaks appear at ﬁrst
inspection more or less intense than they really were. The error
on each 2D-NOESY cross-peak was set at 40% of the measured
height (to take into account both measurement and prediction er-
rors). When there was no signal intensity above the noise of the
spectrum at the cross-peak position where a correlation may have
been possible, a ‘no-NOE’ was assigned. Such no-NOEs were given a
true peak-height of zero and their standard errors were set to a
third of the value of the maximum peak-height calculated from
the height of the noise at the chemical-shift coordinates and the
proton’s scaling factors (i.e., treating the noise as though it could
have been the top of a peak from the most intense multiplet com-
ponent, within 3 standard deviations). All experimental restraints
derived from the NOESY spectra were therefore given both a height
value equivalent for one mole of protons (either a value for NOEs or
zero for no-NOEs) and an associated measurement error. To avoid
the problem of converting no-NOEs into meaningless distance re-
straints for structure calculations, these peak-heights were worked
with throughout (see below). The experimental restraints derived
from the 2D-NOESY spectra in D2O and H2O are shown in Supple-
mentary Tables S10 and S11, respectively.
2.3.3. Residual dipolar couplings
Strained gels were prepared using 4.5% and 6% (w/v) polyacryl-
amide as described previously28 and soaked in a solution of 50 mM
streptomycin in 100 mM D2O pH⁄ 6.0, before insertion into a suit-
ably prepared 5 mm NMR tube. Coupling constants (1JCH) were
measured directly from the acquisition dimension (600 MHz,
4096 complex points, 1.13 s acquisition) of 13C-HSQC spectra re-
corded without broadband 13C-decoupling during acquisition.
Residual dipolar couplings were calculated from the difference in
observed H–C splitting between the two sets of spectra recordedin the free solution and aligned phase. The error in each measure-
ment was estimated from the respective 2D NMR spectra by taking
measurements that were clearly greater or smaller than the ob-
served H–C splittings; errors were 1–2 Hz. The derived experimen-
tal restraints are tabulated in Supplementary Table S12.
2.3.4. 3D-Structure calculations
An initial 3D-structure for streptomycin was built with ﬁxed
bond lengths and angles (based on geometrical constraints rather
than by minimizing a computational chemistry energy function),
which when compared with the Cambridge Structural Database
(CSD) had Mogul Z-scores less than 3 (see below). Ensembles for
streptomycin were constructed by keeping all bonds and angles
ﬁxed and rotating bonds according to a speciﬁc algorithm. Each
rotatable bond was assigned a set of conformer modes, or in statis-
tical thermodynamic terms,macrostates (R); eachmacrostate com-
prising amean torsional angle (l), a spread (r) and a probability (p).
The number of macrostates associated with a bond could be varied
to allow it to adopt several principal conformations, i.e., uni-modal,
bimodal or tri-modal. For example, consider a tri-modal bond
(e.g., sp3–sp3) with three macrostates R1½p1l1r1, R2½p2l2r2,
R3½p3l3r3. Clearly, p1 + p2 + p3 = 1 and thus the macrostate can
be selected using a random number, after which an angle can be
randomly selected for the chosen macrostate using the mean and
spread and standard stochastic computational techniques29 to gen-
erate individual bond microstates. Rules for selection of conformer
macrostates30 are devised for every bond (whichwe terma dynamic
model, see below) and microstates are selected at all rotatable
bonds in the molecule, from which an ensemble of microstates for
the whole molecule is created by repeatedly performing this pro-
cess. For streptomycin, the size of the generated ensemble (total
number of microstates) was ﬁxed at 300, which was found to satis-
factorily cover the molecular conformational space.
The ensemble of microstates, which as a group could collec-
tively represent the conformations actually populated in aqueous
solution, was used to make predictions of experimental data via
an appropriate theory. In the case of the NOESY experiment, in-
ter-proton distances (rij) were averaged over the ensemble accord-
ing to hrij6i and the resultant matrix converted to a relaxation rate
matrix by multiplication by spectral densities estimated from an
overall tumbling correlation time (sc). The relaxation matrix
ﬁrst-order rate equation was solved using diagonalization methods
described previously.31 The predictions of cross-peak heights pro-
duced by this method were used directly in structure calculations
without further processing. The predicted cross-peak heights were
compared against the experimentally measured cross-peak heights
by means of a chi-square least-squares function (see below). The
value of sc was optimized during structure calculations to ensure
the best possible agreement between predictions and experimen-
tal data. It should not be considered that only the NOEs (or no-
NOEs) between protons separated by rotatable bonds contain use-
ful conformational information because the observed intensities of
those NOEs between protons related by ﬁxed geometries within
the molecule (e.g., intra-ring) should also be correctly predicted
in the ﬁnal 3D-structure; in short, all cross-peak positions contain
conformational information and all should be correctly predicted
by the ﬁnal 3D-structure. To predict scalar couplings, standard Kar-
plus equations were employed26,32 and the calculated values (J)
were averaged over the ensemble hJi and used in structure calcula-
tions without further modiﬁcation. Residual dipolar couplings
were calculated from the ensemble using a method based on
molecular shape, described previously33, in combination with a
generalized alignment tensor.34 The dependence on angle is highly
non-linear and thus an extra error correction was applied to the
experimental error dependent upon the angle (see Supplementary
data).
Table 1
Summary of v2 ﬁt for all structural restraints
Dataset No. of restraints Total v2 v2/restraint
2D-NOESY (D2O)
NOEs 167 139.1 0.8
no-NOEs 54 19.4 0.4
2D-NOESY (H2O)
NOEs 9 13.2 1.5
no-NOEs 39 6.1 0.2
Residual dipolar couplings
6% Gel 15 6.9 0.5
4.5% Gel 20 5.3 0.3
Scalar couplings 5 4.8 1.0
Total 309 194.9 0.6
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the goodness of ﬁt between the experimental data (xexp) and the
theoretical predictions (xpred), which is the sum of the square dis-
tances between prediction and experiment, divided by the square
of the estimated error (2exp) on each experimental measurement.
For the ensemble the ﬁtness function v2 was calculated from the
predictions and the measured experimental data. A computer opti-
mization was conducted to minimize v2 by varying the probabili-
ties, means and spreads for each state, until the best ﬁt was found
using 10000 steps of the Metropolis Monte–Carlo method.35 This
optimization was typically run 96 times (with random starting
conﬁgurations) and the 10% of runs with the lowest v2 were com-
pared to ensure that the optimization had converged to the same
set of conformations.
There are nine rotatable bonds in streptomycin (Fig. 1) that can
adopt one or more conformations (four in the glycosidic linkages
and ﬁve exocyclic groups). As in other NMR structure-determina-
tion processes, iterative rounds of calculations were performed in
which the types of bond macrostates (bi-modal, tri-modal) applied
to each bond within streptomycin was varied. The ability of each of
these dynamic models to predict the observed experimental data
was scored. The models were altered until the best possible ﬁt
found (in particular that all experimental data were correctly pre-
dicted) and that the calculations had converged to a consistent set
of conformations. Initial rounds of structure calculations used as
many unambiguous structural restraints as possible and were per-
formed with dynamic models that allowed each rotatable bond to
adopt three different mean angles of any value, each with atten-
dant ﬂoating libration amplitudes (i.e., tri-modal behaviors of
unspeciﬁed geometries). When the experimental data were seen
to deﬁne consistently the behavior of bonds as having only one
or two mean angles (i.e., uni-modal or bi-modal), the dynamic
model was reduced accordingly. As the structure became more de-
ﬁned, ambiguous restraints could be assigned and were included
more speciﬁcally. Also, as data were included they could eventu-
ally be used to determine pro-chiral stereo-assignments by sys-
tematically performing calculations on the two NMR-degenerate
combinations at each center and selecting the combinations with
the lowest v2-score. Bonds that were seen to settle on classic rot-
amer angles (i.e., 60, 180, 300) had their macrostates ﬁxed in la-
ter rounds of structure calculations. Ring pucker was handled by
changing the dihedral angles in the ring to canonical pucker states.
In this way, all possible puckers could be tested against the exper-
imental data individually and in combination with other puckers
by linking the sets of dihedral angles to higher modes (bi-modal,
tri-modal).
Once no change to the dynamic model could reduce the total
v2-score, then it was declared as the ﬁnal dynamic model (see Sup-
plementary Tables S9-S12 for ﬁnal v2-scores for each restraint).
For streptomycin no other fundamentally different model could
be found that could achieve this (i.e., the solution was singular).
Furthermore, assuming that the restraints are spread evenly
throughout the molecule (as they were in streptomycin; see Sup-
plementary Table S13), then the ensemble of microstates produced
by this ﬁnal model was able to predict all experimental data simul-
taneously and hence this ensemble must be a good approximation
to the Boltzmann distributed dynamic conformations of strepto-
mycin in solution. Two sets of structures were output at the end
for use in medicinal chemistry or otherwise (see Supplementary
data).
The ﬁrst set of co-ordinates was an ensemble with 250 individ-
ual conformational microstates that are generated from the full dy-
namic model. Individual conformations that brought atoms closer
than allowable according to the CSD (e.g., S1 O5 and R2 O4 closer
than 2.4 Å) were trimmed from the ﬁnal output conformational
ensemble and replaced by another acceptable conformation toretain a total of 250. This modiﬁcation allowed the total v2 score
to be decreased slightly, but the mean values for each mode were
essentially unperturbed. Modiﬁcations of this type were kept to an
absolute minimum in order to minimize counter-productive artiﬁ-
cial distortions to the set of 3D-structures.36
The second set of co-ordinates was a more degenerate set of
conformational macrostates, comprising only the mean states
(without libration), which is effective in detailing the major confor-
mational states and their populations (calculated from the proba-
bilities of the underlying states). Trivial bond rotations not
affecting the overall conformation of the molecule, e.g., methyl
rotation were effectively removed from this set by grouping them
together.
2.4. Comparison of bond lengths and angles with the Cambridge
structural database
An analysis of the correctness of the 3D-structures (particularly
bond lengths and bond angles) used in this work was conducted by
comparing themwith data from the Cambridge structural database
(CSD)37 via the Mogul software package.38 Where bond lengths or
bond angles deviated signiﬁcantly from those observed previously,
it is most likely that there is an error in model building that should
be addressed.39 The threshold for rejecting a 3D-structure was a
Mogul Z-score of more than 3. All input structures, calculated con-
formational microstates and macrostates for streptomycin were
conﬁrmed to have Mogul Z-scores less than 3, indicating that all
values fall within the set of more than 99% of previous
observations.
2.5. Computational modeling of streptomycin
Torsional proﬁles were constructed for streptomycin by scan-
ning the two //w-angle pairs at intervals of 10 in a grid-like fash-
ion. Each conformer was optimized for every other conformational
variable except the //w angles under consideration using the Mac-
romodel package,40 with the OPLS2005 force-ﬁeld,41 an implicit
GB/SA model for water.42 Following optimization the ﬁnal energy
was recorded to allow construction of a contour plot and the coor-
dinates stored for later analysis, e.g., of ring puckers.
3. Results
3.1. Structural restraints
In total, 309 experimental structural restraints were used to
deﬁne the dynamic 3D-structure of streptomycin (Table 1; see
Supplementary Tables S9-S12 for details), comprising nuclear
Overhauser enhancements (NOEs), scalar couplings and residual
dipolar couplings. The values of the v2 per restraint score between
Table 3
Torsion angle conformational preferences for streptomycin in aqueous solution
Torsiona Modeb Mean angle Libration amplitudec Occupancyd
Glycosidic linkages:
/12 1 75 ± 7 16 ± 7 1.00 ± 0.05
w12 1 134 ± 17 22 ± 6 1.00 ± 0.05
/23 1e 103 ± 6 6 ± 1 0.62 ± 0.16
2e 81 ± 9 10 ± 5 0.38 ± 0.16
w23 1e 103 ± 8 12 ± 7 0.62 ± 0.16
2e 173 ± 14 25 ± 11 0.38 ± 0.16
Exocyclic:
v1(S1) 1 78 ± 5 17 ± 9 0.50 ± 0.05
2 162 ± 5 17 ± 9 0.50 ± 0.05
v3(S1) 1 128 ± 13 27 ± 13 1.00 ± 0.05
v3(R2) 1 180 ± 5 20 ± 11 0.51 ± 0.04
2 300 ± 5 20 ± 11 0.45 ± 0.06
3 60 ± 5 20 ± 11 0.04 ± 0.03
v2(G3) 1 257 ± 8 18 ± 7 1.00 ± 0.05
v5(G3) 1e 315 ± 7 25 ± 14 0.62 ± 0.16
2e 296 ± 27 25 ± 14 0.38 ± 0.16
a Degrees of freedom and their associated dihedral angles are as deﬁned in Figure
1.
b Macrostates are classiﬁed as distinct if rotation of the bond between the two
conformations passes through a van der Waals maximum.
c The libration amplitude corresponds to the range of angles from the average
value that the bond typically adopts in solution.
d The occupancy of each conformation is expressed as a proportion of the total for
that bond.
e The two conformations adopted by the /23, w23 and v2(G6) torsions are mutually
dependent.
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was uniformly weighted in the ﬁnal structure. The majority of
NOE restraints were measured from a sample in D2O and the NOEs
in this dataset were well predicted (v2 per restraint = 0.8). NOE re-
straints measured from a sample in H2O to the exchangeable guan-
idinium hydrogen atoms are the most poorly predicted (v2 per
restraint = 1.5), probably because the differential exchange rates
of the guanidinium hydrogen atoms with respect to each other
made accurate measurement of relative cross-peak heights difﬁ-
cult. In total, 116 NOE and 87 no-NOE inter-residue restraints were
measured (Table 2), allowing the conformational behavior of the
glycosidic linkages in particular to be thoroughly interrogated
and characterized. The residual dipolar coupling measurements,
which are particularly sensitive to the global shape of the
molecule, were very well predicted by the dynamic 3D-structure
(v2 per restraint <0.5) indicating moreover that the overall shape
of the molecule was correct. The structural restraints were evenly
distributed throughout the molecule and therefore all parts of the
molecule were comparably deﬁned (Supplementary Table S13).
Furthermore, individual datasets (e.g., the residual dipolar
couplings or NOEs) could each be used in the absence of the others
to predict essentially the same conformational ensemble indepen-
dently; albeit to a lower accuracy (this also indicates that the pres-
ence of the gel has not perturbed the shape of streptomycin and
that therefore the residual dipolar couplings are reliable). When
all the data was used simultaneously the overall accuracy of the
structure improved substantially.
3.2. A more accurate dynamic view of streptomycin
As shown in Figure 1, there are nine rotatable bonds in strepto-
mycin (four in the glycosidic linkages and ﬁve exocyclic groups) and
three saturated rings that needed to be characterized to describe
fully the solution structure of streptomycin. The dynamic structure
should be interpretable in statistical thermodynamic terms if it is
to be useful as a predictive medicinal chemistry aid. The most
straightforward representation of the dynamic structure (as de-
scribed in Table 3) is a set of 3D-structures that reﬂect uniform sam-
pling from the Boltzmann distribution (i.e., as used in the structure
determination process itself); this set will be referred to as the set of
conformational microstates (in this case comprising 250 3D-struc-
tures) and shown in Figure 2A. Another helpful simpliﬁcation of the
actual dynamic solution behavior is the set of the major conforma-
tional states at each bond (e.g., a bondwith twomajor states will be
bi-modal), which are referred to as macrostates. In this case, strep-
tomycin as a whole was found to have 12 conformational macro-
states (shown in Fig. 2B). The macrostates represent major
conformations around which the microstates librate.
Following conformational reﬁnement it was found that the
experimental data had constrained the solution structure to a
remarkably limited and well-deﬁned set of conformations
(Fig. 2), principally due to the behavior identiﬁed at the two glyco-Table 2
Composition of NOE restraints
Classiﬁcation NOEs noNOEs All
Intraresidue
S1 9 5 14
R2 19 0 19
G3 32 1 33
Total 60 6 66
Interresidue
S1–R2 39 19 58
R2–G3 56 17 73
S1–G3 21 51 72
Total 116 87 203sidic linkages and the R2 ribose ring pucker. The R2 ribose ring
conformation was very clearly deﬁned as being uni-modal and 4E
(to the nearest twist/envelope conformation, i.e., 144 ± 9). The
large vicinal 3JHH coupling constants, sterics and residual dipolar
couplings deﬁned the S1 streptidine and G3 glucosamine rings as
1C4 and 4C1 chairs, respectively. The S1–R2 linkage adopts a single
mean conformation (/1,2 = 75 ± 7,w1,2 = 134 ± 17; see Table 3),
about which it librates (/1,2 = 16 ± 7, w1,2 = 22 ± 6). The
R2–G3 linkage adopts a bi-modal behavior, librating about two
distinct conformations (primary, 62 ± 16%, /2,3 = 103 ± 6, w2,3 =
81 ± 9; secondary, 38 ± 16%, /2,3 = 103 ± 8, w2,3 = 173 ± 14).
The more populated primary mode has a restricted range of
movement with small librational amplitudes (/2,3 = 6 ± 1,
w2,3 = 12 ± 7), while the secondary mode has larger librational
amplitudes (/2,3 = 10 ± 5, w2,3 = 25 ± 11) that are similar to those
of the S1–R2 linkage. The R2 C3’ gem-diol group (v3(R2)) occupies
all three classic rotamer positions, with the experimental data dis-
tinctly disfavoring the 60 conformation during reﬁnement (only
4 ± 3% of the total). The G3 secondary amine (v2(G3)) prefers a sin-
gle conformation independent of the conformation of the R2–G3
linkage. The S1 C1 guanidinium group (v1(S1)) is best ﬁt by a bimo-
dal behavior (average angles symmetrical about the S1 H1 hydro-
gen) that is independent of any other motions in the molecule. In
contrast, the S1 C3 guanidinium group (v3(S1)) distinctly prefers a
uni-modal behavior. It is suggested that this is caused by steric
interactions with the G3 C6 hydroxymethyl group. Supporting this,
the chemical shifts of the protons of the guanidinium group at N31
are distinctly resolved from N32, which has the 15N and 1H chem-
ical shifts characteristic of exposure to bulk solvent. Since the G3
C6 hydroxymethyl group is in very close contact with this guanid-
inium group (Fig. 2B and C) in both conformations of the R2–G3
linkage, it might therefore be expected that the hydroxymethyl
conformation (v5(G6)) would depend on the R2–G3 linkage. Indeed,
the best ﬁt to the experimental data was observed when the v5(G5)
bond adopted slightly different mean angles for each R2–G3
linkage conformation. In both R2–G3 linkage conformations the
best ﬁt model for the v5(G5) bond was a uni-modal behavior with
an average angle close to the ideal rotamer position of 300.
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All the measured experimental data was satisfactorily described
by a dynamic 3D-structural model in which streptomycin librates
about just 12 macrostates (Fig. 2B; two conformations for the
R2–G3 linkage, permuted by three for the R2 C30 gem-diol group
v3(R2) and a further two for the S1 C1 guanidinium group v1(S1)),
whose overall occupancies can be readily calculated from Table 3.
Since only the two distinct conformations of the R2–G3 linkage
signiﬁcantly affect the overall shape of the molecule, it is helpful to
cluster the 12 conformational macrostates into two distinct fami-
lies (Fig. 2C) dependent upon this linkage. From Table 3, the popu-
lations of Family 1 and Family 2 are measured to be 62% and 38%,
respectively, (with an error of 16% either way on this split). The ex-
tent of libration within each family relative to the mean position
for each conformation is shown in Figure 2D. It is important to note
that the spread shown in Figure 2D is not indicative of the error in
the structure determination process, but represents the true dy-
namic range of motion of the molecule in solution.
3.4. Inferred intramolecular interactions
Across the S1–R2 linkage, the S1 O2 hydroxyl group is posi-
tioned very favorably to donate a hydrogen bond to the R2 O5
ether oxygen in the set of conformational macrostates (S1 O2–R2
O5 distance = 2.7 Å; see Supplementary Fig. S5). Consistent with
this, the S1 HO2 proton is visible in NMR spectra up to 25 C (fully
10 C higher than any other hydroxyl proton in streptomycin),
indicating that it is markedly less susceptible to exchange with
bulk solvent for some reason. However, its large temperature coef-
ﬁcient (11.9 ppb/K) indicates that if this hydrogen bond forms, it
is probably only partially populated and highly transitory, reﬂec-
tive of the nature of this type of hydrogen bond.
In the set of macrostates of the dominant mode of the R2–G3
linkage (i.e., Family 1), the G3 HN21 hydrogen is very well posi-
tioned to form a transitory hydrogen bond with either gem-diol
oxygen (R2 O31 & O32) as the v3(R2) bond rotates having near-opti-
mal distances of 2.7 Å (N21–O31/32) and 1.7 Å (HN21–O31/32) and
an angle (N21–HN21. . .O31/32) of 158.43 It is noted that the 60
conformation for the gem-diol group does not allow this hydrogen
bond to form because it positions the R2 H31 proton towards the
G3 HN21 proton. As assessed by the set of conformational micro-
states, there are also multiple potential transient hydrogen-bond
interactions between the S1 C3 guanidinium group and the G3 res-
idue (S1 HN311-G3 O6 & O5, S1 HN3-G3 O6 & O5) that could be
reached through libration within the Family 1 set of conformations.
In the less populated mode of the R2–G3 linkage (i.e., Family 2),
the G3 HN21 hydrogen is not close enough to form a transient
hydrogen bond to either gem-diol oxygen. In the set of conforma-
tional macrostates (i.e., at the average linkage positions), G3
HN21 is also not close enough to the R2 O3 oxygen atom to make
a transient hydrogen bond; however, the set of microstates show
that it can be reached through libration. There are also some poten-
tial transient hydrogen-bond interactions between the S1 C3 guan-
idinium group and the G3 residue (S1 HN311-G3 O6 & O4) that
could be reached through libration. The fewer (and likely less occu-
pied) potential transient hydrogen bonds in Family 2 compared to
Family 1 may underlie its lower abundance in aqueous solution.
4. Discussion
4.1. Comparison with the prior NMR solution structure
A prior combined NMR and molecular dynamics study utilized
14 experimentally-determined structural restraints (13 NOE, 1
3JHH) in restrained molecular dynamics simulations to characterizethe conformation of streptomycin in aqueous solution.44 This work
concluded that streptomycin adopts two main conformations in
solution (S1–R2 /1,2 55, w1,2 25 & /1,2 30, w1,2 50; R2-G3
/2,3 55, w2,3 45 & /2,3 30, w2,3 60), in which both linkages
change conformation together in a concerted motion. In contrast,
the dynamic 3D-structure determined in this work with 309 exper-
imentally-determined structural restraints without restrained
molecular dynamics simulations indicates that the linkages adopt
quite different conformations (S1–R2 /1,2 75, w1,2 134; R2–
G3 /2,3 103, w2,3 81 & /2,3 103, w2,3 173) and that their mo-
tions are not concerted. A third minor (<4%) linkage conformation
was also concluded to be necessarily present in this earlier work in
order to account for two particular NOEs (R2 H2-S1 H4 and R2 H4-
G3 H4), however these NOEs ﬁt the two-family dynamic 3D-struc-
ture determined here extremely well (v2 scores of 0.56 and 1.06,
respectively) without the presence of this third conformation in
the ensemble.
The previous study of streptomycin concluded that the ribose
ring was ﬂexible, presenting two populations with puckering val-
ues of 100–175 (E3/4T4/4E/4TO) and 210–300 (1E/1T2/
E2/3T2/3E/3T4), however the larger set of experimental data used
here is only consistent with a single moderately rigid pucker with
an angle of 144 ± 9 (4E). Using four structural restraints to the R2
H30 proton in the restrained molecular dynamics simulations, the
gem-diol group was previously determined as being in a single
antiperiplanar conformation. However, based upon 35 structural
restraints, this work concludes that a second major conformation
is necessarily present at the gem-diol group to account for all the
observed experimental data.
4.2. Comparison with protein/RNA-streptomycin complex
structures
The conformation of streptomycin bound to the bacterial 30S
ribosomal subunit (its natural target), has been determined to
3.0 Å (PDB code 1FJG)45,46 and to 3.5 Å (PDB codes 4DR3 and
4DR5–7) in a range of apo- and tRNA-bound states. An overlay of
the coordinates of the highest-resolution structure (PDB code
1FJG) with the most populated mode conformation in aqueous
solution (i.e., the Family 1 linkage conformation) demonstrates
that (within error of the crystal structure) the most populated con-
formational family in aqueous solution is the same as the bioactive
conformation (Fig. 3). This can also be seen in Figure 4, where gly-
cosidic angle torsions have been plotted for the structure deter-
mined here (in grey) and for the bioactive conformation (blue).
Comparison of the lower resolution bioactive structures (cyan) also
shows that streptomycin has the same conformation at both link-
ages, irrespective of the ribosomal state. Interestingly, the spread
of these bioactive conformations is similar to the librational spread
measured in solution (although this might be a consequence of the
lower resolution). It is therefore difﬁcult to ignore the obvious
implication, namely that the unbound solution conformation of
streptomycin has been selectively optimized to be as favorable as
possible for interacting with its target; that is, the unbound solu-
tion conformation of streptomycin is pre-organized for optimal
binding.
Considering the unbound and bound structures of streptomycin
in more detail (Figs. 2 and 3), the highest-resolution crystallo-
graphically-derived bioactive conformation of the S1–R2 linkage
is within 14 of the mean position (dark grey) adopted in solution
(and, within error, is indistinguishable). Moreover, all the bioactive
conformations lie within the ensemble of microstates naturally ex-
plored in solution (light grey). The bioactive R2–G3 linkage confor-
mations are also very similar to the Family 1 linkage average
position and lie within the ensemble of microstates this linkage ex-
plores in solution. The highest-resolution bioactive R2 ribose ring
Figure 3. Overlays of the dynamic conformation of streptomycin in aqueous solution (carbon atoms in white) with conformations derived from X-ray crystallographic studies
(carbon atoms in blue or green). (Left) The bioactive conformation of streptomycin (blue) from its co-complex with the 30S ribosome particle (PDB code 1FJG) is very similar
to Family 1 conformational macrostates (the most populated) present in aqueous solution, demonstrating that the bioactive conformation of streptomycin is encoded within
its preferred unbound solution conformations. (Right) The free crystal structure of streptomycin oxime shown in green57 corresponds closely to Family 2 conformational
macrostates present in aqueous solution. As would have been predicted on steric grounds from the dynamic conformation of streptomycin (see Fig. 2A), derivatization to the
oxime has apparently not signiﬁcantly affected the conformational preferences of the F2–G3 glycosidic linkage. Molecules were overlaid on the heavy atoms of the rings from
all 3 residues.
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unbound (144 ± 9; 4E) (see Supplementary Fig. S6). All the exocy-
clic torsion angles of the highest resolution structure (and many of
the lower resolution structures) are also found at either the mean
position of solution macrostate conformations or within the un-
bound librational range (Fig. 5).
While most of the bond lengths, angles and torsions within the
highest-resolution bound conformation of streptomycin are in
good agreement with the existing CSD data (see Table 4), the con-
formation of the S1 C1 guanidinium group is particularly unusual
(with a signiﬁcant twist that breaks the planarity of the group).
Even though this group forms distinct interactions with the ribo-
some, such a conformation has never been observed in solution
and is so energetically unfavorable that it seems quite improbable.
However, were this group to retain the ﬂexibility observed when
unbound upon binding (i.e., oscillation between two modes; see
Figs. 2C and 5), the electron density map could be effectively ac-
counted for; it is therefore proposed that the X-ray data is better
accounted for by a structural model in which the ﬂexibility ob-
served in solution for this group is retained on binding.
The bound conformation of streptomycin is given in the free
aldehyde form (Fig. 3), rather than the hydrated gem-diol form that
predominates in aqueous solution (97%). This difference could be
accounted for by proposing that only the aldehyde form is able
to bind, that streptomycin dehydrates within the binding site or
that there was insufﬁcient resolution in the electron density map
to observe the additional oxygen atom.
Two different crystal forms of the complex between streptomy-
cin and 40-mer RNA aptamers have been reported.47,48 These apta-
mers were selected using dihydrostreptomycin coupled to
sepharose and speciﬁc binding to the S1 C1 guanidine group of
dihydrostreptomycin was achieved using bluensomycin for coun-
ter-selection. In spite of this selection environment being so differ-
ent to free solution conditions, the two aptamer bound
conformations remain remarkably similar to those seen in the un-
bound state at both linkage (Fig. 4) and exocyclic torsions (Fig. 5);indeed, the two crystal forms themselves are more different from
each other than they are from the free dynamic-3D structure.
Streptomycin binds with low-afﬁnity to aminoglycoside-20 0-
phosphotransferase, and three different bound co-complex confor-
mations were reported from a single crystal.49 Since streptomycin
binds with low-afﬁnity, it might be expected that the bound con-
formations differ signiﬁcantly from those seen in the unbound
state. Unfortunately, the bound conformations have a high number
of unlikely bond lengths and angles (as assessed by Mogul38) and
several stereocenters are incorrect. Furthermore, this crystal struc-
ture could not be independently validated by reproduction,50
which is highly suggestive of a problem with the original reﬁne-
ment. Given these problems, it is difﬁcult to make conclusive com-
parisons with the free solution structure. Nevertheless, the
conformations of the R2–G3 glycosidic linkage lie within the range
of conformations seen in solution (Fig. 4) and several exocyclic tor-
sion angles correspond well with both free and enzyme-bound
forms of streptomycin (Fig. 5). It is notable that the S1–R2 linkage
conformations lie within regions predicted computationally to
have the highest energies (Fig. 4), which may represent either a
problem with the structure or (if genuine) may account for the
low binding afﬁnity. Streptomycin also binds to a range of bacterial
resistance enzymes. Experimental observations have concluded
that regardless of the type of resistance enzyme bound to, the con-
formations of the aminoglycoside rings are identical51,52 and are
similar to those observed here in solution.
4.3. Comparison with free crystal structures
Assessment of the unbound solution structure presented here
with the CSD shows that in 90.4% of the observed macrostates
the torsion angles are not unusual (according to Mogul38), which
indicates that the 12 conformations are highly consistent with
crystal structure data across most of the torsions (see Table 4).
The G3 amine group (v2(G3)) has an unusual torsion (when com-
pared to the CSD using Mogul) with a slightly eclipsing interaction
Figure 4. (Top) Comparison of the glycosidic linkage torsion angles for the aqueous solution dynamic 3D-structure of streptomycin determined in this work (grey) with
published crystal conformations (colors). The extent of libration at each linkage is taken from the set of conformational microstates (light grey) while the average positions
are taken from the set of conformational macrostates (dark grey). The S1–R2 linkage (left) adopts a uni-modal conformational distribution in solution, whereas the R2–G3
linkage (right) adopts a bi-modal distribution. The highest resolution bioactive conformation (i.e., when streptomycin is bound to the ribosome, PDB code 1FJG) is shown in
blue, lower resolution ones in cyan (PDB codes 4DR3,5–7) and the free crystal structure57 is in green. The conformations of streptomycin bound to artiﬁcially-selected RNA
aptamers (1NTA, 1NTB) are given in yellow (one conformation of the S1–R2 linkage lies directly below the blue bioactive conformation so is not visible) and the three
conformations measured from the off-target low afﬁnity co-complex with aminoglycoside-6-adenyl-transferase are given in red (3HAV). (Bottom) A computational chemistry
grid-search performed at each of the glycosidic linkages of streptomycin. Energies (kcal/mol) are shown in false color (see key) and comparison with the top panel reveals that
the dynamic solution 3D-structure of streptomycin determined here has found all low energy basins for the molecule solely on the basis of experimental data. Also, it is noted
that aminoglycoside-6-adenyl-transferase (3HAV) conformations shown in the top panel in red lie within regions predicted computationally to have the highest energies.
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presence of an intramolecular hydrogen bond between G3 HN21
and R2 O31/O32, which requires this group to adopt this orienta-
tion, is considered to be the cause of this. The /2,3 angle in Family
2 was also ﬂagged as unusual by Mogul. While there are many ob-
served torsions within a few degrees of that present in the set of
solution conformational macrostates (81 ± 9), the majority of
the recorded observations are larger, between 110 and 120.
It is hypothesized that this conformer is induced by steric and
hydrogen-bond interactions between G3 and S1, and is besides
very similar to that seen in the streptomycin oxime small molecule
crystal structure (see below). The set of conformational micro-
states includes a slightly larger number of unusual torsions,
although the total percentage of unusual torsions (when compared
to the CSD) is only a little changed (73.8%), despite the increased
coverage of conformational space. The dynamic 3D-structure
determined in this work is therefore consistent with small-mole-
cule crystal experimental data, giving an independent validation
of the new NMR-methodology used to determine it.
Although the free crystal structure of streptomycin itself has
not been reported, the coordinates of the R2 C30 oxime derivative
are available. As expected, this structure is in excellent agreement
with existing CSD data. The only torsion in the free solution dy-
namic 3D-structure that is ﬂagged as unusual by Mogul is /2,3,with an angle of 64. While this torsion is quite different from
the majority of observations (110 to 120), it is nevertheless
within a few degrees of several observed torsions. Analysis of the
crystal structure indicates that this conformer is probably induced
by formation of an intramolecular hydrogen bond between G3 O4
(acceptor) and S1 N31 (donor), as concluded for the dynamic 3D-
structure when unbound above.
An overlay of the coordinates of the streptomycin oxime crystal
conformation with the less populated Family 2 linkage conforma-
tion (Fig. 3) shows remarkable similarity. The S1–R2 glycosidic
linkage conformation is similar to the average position adopted
when unbound and clearly lies within the ensemble of conforma-
tions naturally explored in solution. The R2–G3 linkage conforma-
tion is also very similar to the Family 2 linkage average position
and lies within the ensemble of conformations seen when un-
bound. The ribose ring pucker conformation (123; 4T3) is again
adjacent to that seen when unbound (144 ± 9; 4E) and all the exo-
cyclic torsion angles are also found at average positions of solution
macrostates or within the unbound librational range (Fig. 5).
Given the packing interactions, numerous interactions with
water molecules and selenate ions present in the free crystal, it
is remarkable that the crystal conformation is so very similar to
one of the two main conformations naturally present in aqueous
solution. However, since the crystal structure is likely to be a low
Figure 5. Circular histograms comparing the exocyclic torsion angles for the solution 4D-structure of streptomycin determined in this work (left, grey) with published crystal
conformations (right, colors). Colors are as in Figure 4 (blue/cyan = bioactive; green = free crystal; yellow = RNA aptamers; red = off-target interaction). Conformations were
binned at 15 intervals, centered on 0 at north and proceeding clockwise.
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Table 4
Mogul analysis of torsion angles in streptomycin 3D-structures
Structure Mogul categorya
No hits (%) Not unusual (enough hits) (%) Not unusual (few hits) (%) Unusual (enough hits) (%) Unusual (few hits) (%)
Dynamic 3D-structure:
Idealised-4D 0 67.3 23.1 9.6 0
Ensemble-4D 0 57.7 16.1 19.2 7.0
Steptomycin oxime selenate free crystal:
STOSEH10b 0 83.3 12.5 4.2 0
Protein-bound crystal structures:
1FJGc 4.4 65.2 0 21.7 8.7
a Mogul36 uses heuristics to identify torsion types that are similar to those in a query molecule, providing a statistical overview of previously observed values. The
heuristics ﬁnd a representative set of similar features, taking into account the local context of the query atoms. Torsions are divided into ﬁve categories. The ‘unusual (enough
hits)’ category is of most concern, indicating that the current torsion is not consistent with a signiﬁcant number of previous observations.
b CSD.
c PDB entry codes.
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tion are also low (free) energy, this is not necessarily surprising.
The replacement of the gem-diol group with the oxime is sterically
very feasible and would not be expected to perturb the conforma-
tional energy landscape of the R2–G3 linkage on steric grounds
(compare Figs. 2A and 5). However, since the oxime is only able
to form one hydrogen bond with G3 HN21 (to the oxime nitrogen)
while the gem-diol can make two (to O31 and O32, see above), the
balance between Family 1 andFamily 2 linkage conformations may
be shifted (and may therefore have favored the crystallization of
streptomycin oxime in the Family 2 conformation).
Comparison of the ensemble of structures calculated here with
energy surfaces at the two glycosidic linkages derived from
computational chemistry (Fig. 4) shows that all experimentally-
determined conformers correspond to low energy regions. Further-
more, there are no low energy basins predicted by computational
chemistry that are not identiﬁed by this NMR method, providing
conﬁdence that all of the major conformational states populated
in solution can be identiﬁed without a computational chemistry
force ﬁeld.
4.4. Free ligand solution structures in medicinal chemistry
Based exclusively on experimental data, this high resolution dy-
namic 3D-structure of streptomycin in free solution provides a
concrete example of conformational pre-organization for binding.
While the multiplicity of interactions present in a single protein-li-
gand complex is an enthalpy/entropy compromise that is almost
impossible to separate,53 the fact remains that high-afﬁnity ligands
are quite likely to have low entropic barriers to binding, i.e., an
ability to move readily from the free solution set of conformations
to the bound set of conformations will naturally improve the bind-
ing afﬁnity. The energy required to conformationally restrict and
organize a free ligand into its bound conformation is always unfa-
vorable and, while this penalty can be paid for via other binding
energies (e.g., hydrogen bonding, desolvation), where high-afﬁnity
interactions are observed it is intuitively clear that a low confor-
mational energy barrier is often likely to be a signiﬁcant contribut-
ing factor. Therefore, it would not be surprising if conformational
pre-organization for binding, as seen here for streptomycin, were
in fact commonly observed.
A second important point to note from this study is that the free
crystal 3D-structure, the bioactive conformation and other bound
conformations are likely to be present in the free solution ensem-
ble. However, free ligand crystal structures, while more predictive
than computational chemistry (performed in vacuum), may bear
little resemblance to the bioactive conformation.54 Therefore,
accurate free ligand free solution 3D-structures are likely a morereliable predictor of the bioactive conformation than a single free
ligand crystal 3D-structure when protein X-ray co-crystallographic
structures are not available.
There are two immediately apparent situations where accurate
unbound NMR solution conformations can be used in medicinal
chemistry: (1) where the bioactive conformation is not available
and hence a precise spatially-deﬁned pharmacophore model can-
not be deﬁned, and (2) in molecular design and optimization for
estimating the barrier to adoption of the bioactive shape when a
protein X-ray co-crystal is available. In either case, contextualiza-
tion of unbound-ligand 3D-structures, structure-activity relation-
ships and protein co-crystallography data go hand-in-hand and
are synergistic.
In the ﬁrst case, the ability to determine accurate unbound 3D-
structures allows ligand-based design methods to be applied.55
These approaches are particularly important for membrane-bound
proteins or for disrupting protein–protein interactions, where co-
crystallography is often intractable. Assuming (for high-afﬁnity li-
gands) that the bioactive conformation is abundant in the free
solution ensemble, a method can be envisaged to identify the bio-
active conformation (and build a 3D-pharmacophore model) even
for ﬂexible ligands in the absence of a protein co-crystal. First, a
set of high-afﬁnity ligands for the same target and binding site
(ideally with different scaffolds) would be identiﬁed, their solution
structures determined and an initial phamacophore model pro-
posed from structure–activity data. Common 3D-shapes are identi-
ﬁed by overlaying unbound structures using 3D-pharmacophore
points. By performing this for several ligands, a restricted set of
overlaying macrostates may be identiﬁable, which would be
hypothesized to contain the presumed bioactive conformation.
Previous approaches have focused on overlaying ligands with their
conformation determined by computational chemistry, which have
not been accurate enough to perform such a process, but with the
advent of accurate NMR-derived ligand free structures this be-
comes a real possibility. Consensus 3D-pharmacophore overlays
are useful for rationalizing 3D-structure-activity relationships
and can also be used to perform hit identiﬁcation, scaffold hopping
or lead optimization by virtual screening of diverse or focused
compound collections using pharmacophores.
In the second case, when the bioactive conformation is already
known, solution 3D-structures of ligands have signiﬁcant utility for
investigating the contributions to the thermodynamics and kinet-
ics of binding. Effective afﬁnity optimization requires an accurate
theoretical understanding of the free energy associated with bind-
ing, which is dependent on bonding (solvation and intermolecular
interactions) and the conformations of the receptor–ligand assem-
bly (before and after binding).53 In particular, comparison of un-
bound ligand ensembles with the bioactive conformation allows
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are dependent on conformation and those that result from bond-
ing. This is essential for rationalizing complicated structure–activ-
ity relationships that result from the fact that bonding opposes
motion and motion opposes bonding during optimization.56 Fur-
thermore, it can also be used to support the design of conforma-
tionally-restricted molecules (e.g., via cyclization) that can be
used to drive the free conformation to the presumed bioactive con-
formation and perhaps to understand extraneous conformations
that could be the source of off-target effects. These approaches
can be used during preclinical drug development in both hit-to-
lead and lead optimization processes.
5. Conclusions
A new NMR method is presented that has the capability to
determine accurately the (unbound) conformations of ligands
and their range of dynamic motion in a physiologically-relevant
solvent environment that is independent of computational chemis-
try. The method is applied to the aminoglycoside streptomycin and
reveals that the molecule has 12 conformational macrostates that
can be grouped into two major families. Comparison with crystal-
lographic data afﬁrms that the bioactive conformation in complex
with the 30S ribosomal subunit is well represented in the most
populated family of free solution structures. Our observation,
based exclusively on experimental data, provides another example
of a high-afﬁnity ligand that is conformationally pre-organized for
binding to its target. Therefore, accurate ligand structures may (in
some circumstances) provide an alternative route to the bioactive
conformation when it cannot be determined by other means.
When the bioactive conformation is already established, accurate
free ligand structures provide a unique context for interpretation
of the thermodynamics and kinetics of binding.Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2013.06.056.
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